Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
暂无分享,去创建一个
P. Russo | G. Colombo | R. Aquino | T. Mencherini | R P Aquino | L Prota | G Auriemma | A Santoro | T Mencherini | G Colombo | P Russo | A. Santoro | G. Auriemma | L. Prota | R. P. Aquino | Paola Russo | Lucia Prota | Antonietta Santoro | Gaia Colombo
[1] A. Ammit,et al. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims. , 2010, International journal of pharmaceutics.
[2] Basma M. Ibrahim,et al. Development of inhalable dry powder formulation of basic fibroblast growth factor. , 2010, International journal of pharmaceutics.
[3] H. Chrystyn,et al. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. , 1999, American journal of respiratory and critical care medicine.
[4] R. Gambari,et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] Lei Wang,et al. Characterization of a new inhalable thymopentin formulation. , 2009, International journal of pharmaceutics.
[6] P. Russo,et al. Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells. , 2011, International journal of pharmaceutics.
[7] J. Raper,et al. How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders? , 2004, Pharmaceutical Research.
[8] N. Chew,et al. Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance , 2001, Pharmaceutical Research.
[9] M S Pepe,et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.
[10] E. Reverchon,et al. Albumin/gentamicin microspheres produced by supercritical assisted atomization: optimization of size, drug loading and release. , 2010, Journal of pharmaceutical sciences.
[11] P. Russo,et al. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[12] M. Evans,et al. Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene , 2002, Journal of Molecular Medicine.
[13] A. Ammit,et al. Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency , 2009, Pharmaceutical Research.
[14] K. Amighi,et al. Formulation strategy and use of excipients in pulmonary drug delivery. , 2010, International journal of pharmaceutics.
[15] M. Rafiee-Tehrani,et al. The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles. , 2005, Journal of pharmaceutical sciences.
[16] J. Birchall,et al. The use of amino acids to enhance the aerosolisation of spray‐dried powders for pulmonary gene therapy , 2005, The journal of gene medicine.
[17] S. Ogston,et al. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. , 1996, Thorax.
[18] J. Clancy,et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.
[19] D. Geller. Aerosol antibiotics in cystic fibrosis. , 2009, Respiratory care.
[20] Reinhard Vehring,et al. Pharmaceutical Particle Engineering via Spray Drying , 2007, Pharmaceutical Research.
[21] J. Rice,et al. Insulin-like Growth Factor-I Levels Predict Weight, Height and Protein Catabolism in Children and Adolescents with Cystic Fibrosis , 2009, Journal of pediatric endocrinology & metabolism : JPEM.
[22] L. Ward,et al. Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease. , 1985, The American journal of clinical nutrition.
[23] J. Conway,et al. Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. , 2008, Journal of pharmaceutical sciences.
[24] A. Smyth,et al. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity , 2010, Current opinion in pulmonary medicine.
[25] B. Kerem,et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.
[26] M. Welsh,et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[27] B. Ramsey,et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. , 1985, The American review of respiratory disease.
[28] P. Seville,et al. Spray-dried powders for pulmonary drug delivery. , 2007, Critical reviews in therapeutic drug carrier systems.
[29] A. Avital,et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. , 2000, American journal of respiratory and critical care medicine.
[30] Cynthia L Stevenson,et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. , 2008, Journal of pharmaceutical sciences.
[31] K. Alzoubi,et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. , 2008, Respiratory care.
[32] Marc Egen,et al. Force control and powder dispersibility of spray dried particles for inhalation. , 2010, Journal of pharmaceutical sciences.